The Latest Cardiac and Vascular News
LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced the launch of the Prospective, Multicenter, Multi-national, Single Arm Trial Evaluating the Efficacy, Safety […]
MENLO PARK, Calif.–(BUSINESS WIRE)–Jupiter Endovascular, Inc., a medical technology startup developing a new class of endovascular procedures using Endoportal Control™, announced today that the first two patients have been treated in SPIRARE I (NCT06571760), a multicenter study of the Vertex Pulmonary Embolectomy System using the company’s Endoportal Control™ platform technology. […]
BERKELEY HEIGHTS, N.J., Sept. 19, 2024 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has entered into a new commercial supply contract with a top-tier mid-sized dialysis operator for the supply of DefenCath® (taurolidine and heparin) to dialysis clinics in the US. This new agreement will provide access to DefenCath for adult patients with kidney failure receiving hemodialysis through a central venous catheter at more than 250 outpatient dialysis clinics located across the United States.
DUBLIN–(BUSINESS WIRE)–The “XARELTO Market Size, Forecast, and Market Insight – 2032” report has been added to ResearchAndMarkets.com’s offering. “XARELTO Market Size, Forecast, and Market Insight – 2032” Post this The latest industry report provides a thorough analysis of the potential growth and impact of XARELTO for the treatment of Peripheral Artery Disease (PAD) in […]
September 17, 2024 12:09 PM Eastern Daylight Time DUBLIN–(BUSINESS WIRE)–The “ZONTIVITY Market Size, Forecast, and Market Insight – 2032” report has been added to ResearchAndMarkets.com’s offering. “ZONTIVITY Market Size, Forecast, and Market Insight – 2032” Post this ZONTIVITY, known for its efficacy in reducing thrombotic cardiovascular events, emerges as a significant pharmaceutical agent in […]
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the introduction of the 160cm FDA approved version of its unique LumiGuide endovascular navigation wire. This enhanced LumiGuide guidewire, which utilizes the company’s breakthrough Fiber Optic RealShape (FORS) technology, was used for the first time on a patient by Professor and vascular surgeon Carlos Timaran, MD, an internationally recognized expert in advanced endovascular techniques. He used the technology during a complex aortic aneurism repair operation, marking the 1000th patient treated milestone using FORS technology since first clinical use of the technology in 2020. The introduction of a longer FORS-enabled LumiGuide Navigation Wire enables US clinicians to visualize a broader range of catheters and expands usage of this technology to patients in America treated in centers equipped with LumiGuide.
Completion of enrollment expected in Q4 with FDA submission for commercialization anticipated by the end of 2024 Completion of enrollment expected in Q4 with FDA submission for commercialization anticipated by the end of 2024
Latest computer assisted vacuum thrombectomy (CAVT) technologies combine superior catheter design with the latest dual clot detection computer algorithms designed to restore blood flow quickly Lightning Flash™ 2.0 will be the most advanced thrombectomy system on the European market to address venous and pulmonary thrombus Lightning Bolt™ 7 is designed […]
PLANO, Texas, Sept. 16, 2024 /PRNewswire/ — Argon Medical Devices, a leading provider of medical device solutions for Interventional Radiology, Vascular Surgery, Interventional Cardiology, and Oncology procedures, announced the launch of the CLEANER Vac™ Thrombectomy System for the…
PALM SPRINGS, Calif., Sept. 6, 2024 /PRNewswire/ — Leading physicians and researchers will present results from 21 clinical trials from Sunday, November 3, to Tuesday, November 5, at the annual VIVA and The VEINS conferences at Wynn Las Vegas. VIVA (Vascular InterVentional Advances) is a…
